164 related articles for article (PubMed ID: 16334115)
1. Antiprostasome antibody titres in benign and malignant prostate disease.
Minelli A; Ronquist G; Carlsson L; Mearini E; Nilsson O; Larsson A
Anticancer Res; 2005; 25(6C):4399-402. PubMed ID: 16334115
[TBL] [Abstract][Full Text] [Related]
2. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability.
Larsson A; Ronquist G; Wülfing C; Eltze E; Bettendorf O; Carlsson L; Nilsson BO; Semjonow A
Urol Oncol; 2006; 24(3):195-200. PubMed ID: 16678048
[TBL] [Abstract][Full Text] [Related]
3. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
4. Antiprostasome antibodies are not an appropriate prognostic marker for prostate cancer.
Stewart AB; Delves GH; Birch BR; Cooper AJ; Lwaleed BA
Scand J Urol Nephrol; 2009; 43(2):104-8. PubMed ID: 18979375
[TBL] [Abstract][Full Text] [Related]
5. Serum antibodies against prostasomal clusterin in prostate cancer patients.
Ronquist KG; Carlsson L; Ronquist G; Semjonow A; Wülfing C; Larsson A
Scand J Clin Lab Invest; 2008; 68(3):219-27. PubMed ID: 17926197
[TBL] [Abstract][Full Text] [Related]
6. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
Lokant MT; Naz RK
Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
8. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
10. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Zisman A; Zisman E; Lindner A; Velikanov S; Siegel YI; Mozes E
J Urol; 1995 Sep; 154(3):1052-5. PubMed ID: 7543596
[TBL] [Abstract][Full Text] [Related]
12. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
13. Is chronic inflammatory change in the prostate the major cause of rising serum prostate-specific antigen in patients with clinical suspicion of prostate cancer?
Chang SG; Kim CS; Jeon SH; Kim YW; Choi BY
Int J Urol; 2006 Feb; 13(2):122-6. PubMed ID: 16563135
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
15. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
Shafer MW; Mangold L; Partin AW; Haab BB
Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
[TBL] [Abstract][Full Text] [Related]
16. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate.
Ischia R; Hobisch A; Bauer R; Weiss U; Gasser RW; Horninger W; Bartsch G; Fuchs D; Bartsch G; Winkler H; Klocker H; Fischer-Colbrie R; Culig Z
J Urol; 2000 Apr; 163(4):1161-4; discussion 1164-5. PubMed ID: 10737487
[TBL] [Abstract][Full Text] [Related]
18. [Effects of chronic bacterial prostatitis on changes in concentration and free and total prostatic specific antigen in the serum and urine from patients with benign prostatic hyperplasia and prostatic cancer].
Mazo EB; Grigor'ev ME; Stepenskiĭ AB
Urologiia; 2001; (5):3-7. PubMed ID: 11641977
[TBL] [Abstract][Full Text] [Related]
19. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
20. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters.
Khorramizadeh MR; Aalizadeh N; Pezeshki M; Ghahary A; Zeraati H; Berahmeh A; Safa O; Saadat F
Int J Urol; 2005 Jul; 12(7):637-43. PubMed ID: 16045556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]